Collagen-povidone for Diabetic Seniors' Tenosynovitis

Topical Collagen-povidone Injection as an Alternative Treatment for Stenosing Tenosynovitis in Older Adults With Type 2 Diabetes Mellitus

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06396819

Enrollment

Registered

2024-05-02

Start date

2023-01-01

Completion date

2024-04-01

Last updated

2024-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Complications

Keywords

intervention, Stenosing Tenosynovitis, Collagen-Povidone

Brief summary

Diabetes affects 415 million adults globally, leading to hand issues. Povidone collagen shows promise in managing tenosynovitis. A clinical trial was conduced to compared its efficacy in adults over 60. It is shown that the intervention reduces pain, improves functionality, and grip strength with no complications. Collagen povidone holds potential for treating diabetic hand issues.

Detailed description

A randomized clinical trial from January 2022 to January 2023 compared povidone collagen intervention with a placebo in adults aged 60 and above suffering from stenosing tenosynovitis. Participants were randomized into Case (collagen-povidone) and Control (physiological solution) groups. The study evaluated parameters like tenosynovitis, diabetes, pain, functionality, and grip strength.

Interventions

DRUGcollagen-povidone solution

Application of collagen-povidone solution at a dose of 0.2 cc, compared with the application of physiological solution in the control group

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Masking description

single-blind

Intervention model description

A therapeutic intervention using povidone collagen vs. placebo was carried out, and the patients were recruited after meeting the inclusion criteria and divided into two randomized groups (Case vs Control). Application of collagen-povidone solution at a dose of 0.2 cc, compared with the application of physiological solution in the control group.

Eligibility

Sex/Gender

ALL

Age

60 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Diagnostic of stenosing tenosynovitis * Diagnostic of diabetes * Adults aged 60 or older

Exclusion criteria

* Adults aged 60 or older

Design outcomes

Primary

Measure	Time frame	Description
Mean evolution time of tenosynovitis	12 months	Tenosynovitis should decreased its progression in the experimental group

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026